Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Plain-language summary
This trial is testing Lenalidomide for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Lenalidomide (DRUG): 25mg po on day 1-10 | Cyclophosphamide (DRUG): 750mg/m² iv on day1 | Doxorubicin (DRUG): 50mg/m² iv on day 1 | Vincristine (DRUG): 1.4mg/m² iv on day 1 | Prednisone (DRUG): 100mg po on day1-5
Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details